The availability of monoclonal CD38 antibodies [25] and the rather restricted expression upon pathological neoangiogenesis in the human BCCs makes the CD38 receptor also an attractive immunotherapeutic target to prevent new vessel formation and thereby tumor growth. The gene discussed is CD38; the disease is neoplasm.